RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

Core Insights - RAPT Therapeutics has appointed Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors, enhancing its leadership team during a critical phase of development [1][2] - The company's lead product candidate, RPT904, is a monoclonal antibody targeting free human immunoglobulin E (IgE) and is currently in Phase 2 trials for chronic spontaneous urticaria and asthma, with plans to initiate a Phase 2 trial for food allergy later this year [1][2] Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases, leveraging proprietary expertise in immunology [5] Leadership Experience - Scott Braunstein, M.D., has over 30 years of experience in the biotechnology and pharmaceutical industries, including roles at Aisling Capital and Marinus Pharmaceuticals, and has served on multiple boards [3] - Ashley Dombkowski, Ph.D., brings over 20 years of experience as an executive and investor, previously serving as CEO of Cellics Therapeutics and co-founding several companies focused on food allergy treatments [4]